Background
Many pregnant women experience anxiety while waiting for the results of diagnostic tests. Policies and practices intended to reduce this anxiety require evaluation.
Objectives
The Amniocentesis Results: Investigation of Anxiety (ARIA) trial tested two hypotheses:
• Giving amniocentesis results out on a fixed date alters maternal anxiety during the waiting period, compared with a policy of telling parents that the result will be issued 'when available' (i.e. variable date).
• Issuing early results from a rapid molecular test alters maternal anxiety during the waiting period, compared with not receiving any results prior to the karyotype.
The effects of the two interventions on anxiety 1 month after receiving karyotype results were also examined.
Design
A multi-centre, randomised, controlled, open fixed sample, 2 × 2 factorial design trial, with equal randomisation.
Setting
Twelve hospitals in England offering amniocentesis as a diagnostic test for Down's syndrome.
Participants
A total of 226 women who had had an amniocentesis were randomised between June 2002 and July 2004. Eight women with abnormal results or test failure were excluded post-randomisation.
Interventions
Two interventions were used in the trial:
• issuing karyotype results on a prespecified fixed date, rather than issuing them as soon as they became available • issuing karyotype results alone, or subsequent to issuing results from a rapid molecular test for the most common chromosomal abnormalities.
Main outcome measures
Three outcome measures were considered:
• average anxiety during the waiting period, calculated using daily scores from the short version of the Spielberger State-Trait Anxiety Inventory (STAI) • recalled anxiety, measured 1 month after receiving karyotype results, using a rating scale • anxiety at the 1-month follow-up, measured using the short-form STAI.
Results
No evidence was found that giving out karyotype results on a fixed or on a variable date altered maternal anxiety during the waiting period. However, the analysis only had sufficient power to detect a moderate to large effect.
Issuing early results from a partial but rapid test reduced maternal anxiety by a clinically significant amount during the waiting period, compared with receiving only the full karyotype results. This was a moderate to large effect.
Additionally, group differences in recalled anxiety reflected fairly closely the differences in anxiety that women had experienced while waiting for results. One month after receiving normal karyotype results, anxiety was low in all groups, but women who had been given rapid test results were more anxious than those who had not. This was a small to moderate effect. 
Recommendations for research
Further research could be considered for the following:
• more qualitative studies into the causes, characteristics and consequences of anxiety associated with prenatal testing
• the effects of different testing regimes on short and longer-term anxiety, on the preferences of women, and on the relationship between anxiety and preference • consideration of the ways in which information might be used to minimise anxiety in different testing regimes • policy implications of incorporating individual preferences for different testing regimes into prenatal testing programmes. NHS R&D HTA Programme T he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.
Publication
The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.
The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, service-users groups and professional bodies such as Royal Colleges and NHS Trusts.
Research suggestions are carefully considered by panels of independent experts (including service users) whose advice results in a ranked list of recommended research priorities. The HTA Programme then commissions the research team best suited to undertake the work, in the manner most appropriate to find the relevant answers. Some projects may take only months, others need several years to answer the research questions adequately. They may involve synthesising existing evidence or conducting a trial to produce new evidence where none currently exists.
Additionally, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme is able to commission bespoke reports, principally for NICE, but also for other policy customers, such as a National Clinical Director. TARs bring together evidence on key aspects of the use of specific technologies and usually have to be completed within a short time period.
Criteria for inclusion in the HTA monograph series
Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.
Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.
